Clinical Trials Logo
  1. Home
  2. MGMT-Unmethylated Glioblastoma
  3. NCT04725214

Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma

MGMT-Unmethylated Glioblastoma Clinical Trial

Official title:
Anlotinib Combined With STUPP Protocol as First-line Regimen for MGMT Nonmethylated Glioblastoma: a Multicenter, Open-label, Single-arm, Phase II Clinical Trial

Clinical Trial Summary

The purpose of this study is to test the efficacy and safety of Anlotinib in combination with STUPP regimen for MGMT promoter nonmethylated glioblastoma.

Clinical Trial Description

For MGMT unmethylated glioblastoma patients undergoing STUPP regimen adjuvant therapy, during adjuvant chemotherapy, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04725214
Study type Interventional
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact
Status Recruiting
Phase Phase 2
Start date January 15, 2021
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05033587 - Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. Phase 2
Active, not recruiting NCT04396860 - Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma Phase 2/Phase 3
Recruiting NCT05879250 - WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Recruiting NCT06186401 - Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells Phase 1
Terminated NCT03250299 - Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Phase 1
Recruiting NCT03107780 - Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer Phase 1
Recruiting NCT05909618 - Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases Phase 2
Not yet recruiting NCT05694416 - Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma Phase 2
Recruiting NCT04224441 - Repurposing Chlorpromazine in the Treatment of Glioblastoma Phase 2
Recruiting NCT05236036 - Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma Phase 1
Active, not recruiting NCT03452930 - Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma Phase 1